Literature DB >> 28137555

Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic non-functioning pancreatic neuroendocrine tumors.

Wenhao Ge1, Dongkai Zhou1, Shaoyan Xu1, Weilin Wang2, Shusen Zheng3.   

Abstract

BACKGROUND: The treatment of non-functioning pancreatic neuroendocrine tumors (NF-PNETs) still remains controversial. It is uncertain whether asymptomatic patients have better prognosis than symptomatic patients and whether surgery is necessary for asymptomatic patients.
METHODS: Patients with NF-PNETs who were managed surgically or by surveillance between June 2007 and December 2013 were retrospectively studied. The choice of surgery or surveillance was based entirely on the patient's desire. Survival prognosis was compared between asymptomatic and symptomatic patients, and evaluated among patients who were under surveillance.
RESULTS: Of the 53 patients with NF-PNETs, 48 (90%) were treated surgically. 25 patients (47%) were symptomatic patients, 23 (43%) asymptomatic, and five (10%) detected by surveillance. Among the latter group, one patient suffered from tumor progression and four had stable disease. When compared with symptomatic NF-PNETs, asymptomatic NF-PNETs showed lower pathology grades (P = 0.006), better 3-year cumulative progression-free survival and overall survival after surgical treatment. Parenchyma-preserving resection was associated with a higher risk of pancreatic fistula (71 vs. 17%, P = 0.007). A positive lymph node status (P = 0.003) and perineural or vascular invasion (P = 0.01) were significant predictors of tumor recurrence or metastasis. Patients with grade G3 disease (P = 0.005) or a tumor size >4 cm (P = 0.019) had poor prognosis.
CONCLUSIONS: Compared with symptomatic NF-PNETs, asymptomatic NF-PNETs had a lower degree of malignancy and better prognosis. Surveillance for small asymptomatic NF-PNETs needs to be further studied.
Copyright © 2017 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Pancreatic neuroendocrine tumors; Parenchyma-preserving resection; Surveillance; Survival

Mesh:

Year:  2017        PMID: 28137555     DOI: 10.1016/j.ijsu.2017.01.088

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  5 in total

Review 1.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

2.  Surgical Strategy and Prognosis of Pancreatic Neuroendocrine Tumors Based on Smart Medical Imaging.

Authors:  Ming Huang; Jian Li; Qinghua Yin; Lixin Xiong
Journal:  Contrast Media Mol Imaging       Date:  2022-06-15       Impact factor: 3.009

Review 3.  Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

Authors:  S M Sadowski; C R C Pieterman; N D Perrier; F Triponez; G D Valk
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

4.  A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor.

Authors:  Asahi Sato; Toshihiko Masui; Nao Sankoda; Kenzo Nakano; Yuichiro Uchida; Takayuki Anazawa; Kyoichi Takaori; Yoshiya Kawaguchi; Shinji Uemoto
Journal:  Surg Case Rep       Date:  2017-07-20

5.  A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms.

Authors:  Yong Gao; Hao Gao; Guangfu Wang; Lingdi Yin; Wenbin Xu; Yunpeng Peng; Junli Wu; Kuirong Jiang; Yi Miao
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.